human monoclonal (AbD18334)
application: ELISA
application: ELISA
ELISA demonstrating the specificity of HCA209 using various antigens as coating reagents. Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% BSA, the anti-Ustekinumab antibody HCA209 (AbD18334; 20µL from a 2µg/mL solution) was added followed by an anti-His-tag antibody conjugated to HRP in HiSPEC buffer (BUF049) . Detection was performed using QuantaBlu™ fluorogenic peroxidase substrate
quantity: 0.1 mg
price: 556 USD
to the supplier
human monoclonal (AbD17829)
application: ELISA
application: ELISA
ELISA demonstrating the specificity of HCA208 using various antigens as coating reagents (A: Human serum, B: human IgG1/kappa from myeloma plasma, C: Rituximab, D: Bevacizumab, E: Adalimumab, F: Alemtuzumab, G: Infliximab, H: Ustekinumab). Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% BSA, the anti-Ustekinumab antibody AbD17829 (20µL from a 2µg/mL solution) was added followed by Mouse anti-V5-tag:HRP (MCA1360P) in HiSPEC buffer (BUF049) . Detection was performed using QuantaBlu™ fluorogenic peroxidase substrate
quantity: 0.1 mg
price: 556 USD
to the supplier
human monoclonal (AbD17827_hIgG1)
application: ELISA
application: ELISA
ELISA demonstrating the specificity of HCA210 using various antigens as coating reagents . Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% milk powder in PBST, HRP-conjugated HCA210 (AbD17827_hIgG1; 20µL from a 2µg/mL solution in BUF049 ) was added. Detection was performed using the QuantaBlu™ fluorogenic peroxidase substrate
quantity: 0.1 mg
price: 652 USD
to the supplier
human monoclonal (AbD17829_hIgG1)
application: ELISA
application: ELISA
ELISA demonstrating the specificity of HCA211 using various antigens as coating reagents (A: Human serum, B: human IgG1/kappa from myeloma plasma, C: Rituximab, D: Bevacizumab, E: Adalimumab, F: Alemtuzumab, G: Infliximab, H: Ustekinumab) and HCA211 conjugated to HRP as the detection reagent. Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% milk powder in PBST, HRP-conjugated HCA211 (20µL from a 2µg/mL solution in HiSPEC buffer, (BUF049) was added. Detection was performed using the QuantaBlu™ fluorogenic peroxidase substrate
quantity: 0.1 mg
price: 652 USD
to the supplier
human recombinant (AbD17827_hIgG1)
conjugate: HRP
application: ELISA
conjugate: HRP
application: ELISA
ELISA demonstrating the specificity of HCA210 using various antigens as coating reagents . Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% milk powder in PBST, HRP-conjugated HCA210 (AbD17827_hIgG1; 20µL from a 2µg/mL solution in BUF049 ) was added. Detection was performed using the QuantaBlu™ fluorogenic peroxidase substrate
quantity: 0.1 mg
price: 728 USD
to the supplier